GlaxoSmithKline Plc and Medicago Inc. said their Covid-19 vaccine candidate spurred protective antibody levels 10 times higher than in patients who have recovered from the disease in interim trial results.
The vaccine generated similar immune responses in all age groups with no serious safety events in the mid-stage trial, Medicago said Tuesday in a statement. About 500 participants ages 18 to 88 received the vaccine, and about 100 got placebo shots.
